flecainide has been researched along with Death, Sudden, Cardiac in 41 studies
Flecainide: A potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial ARRHYTHMIAS and TACHYCARDIAS.
flecainide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2,5-bis(2,2,2-trifluoroethoxy)benzoic acid with the primary amino group of piperidin-2-ylmethylamine. An antiarrhythmic agent used (in the form of its acetate salt) to prevent and treat tachyarrhythmia (abnormal fast rhythm of the heart).
Death, Sudden, Cardiac: Unexpected rapid natural death due to cardiovascular collapse within one hour of initial symptoms. It is usually caused by the worsening of existing heart diseases. The sudden onset of symptoms, such as CHEST PAIN and CARDIAC ARRHYTHMIAS, particularly VENTRICULAR TACHYCARDIA, can lead to the loss of consciousness and cardiac arrest followed by biological death. (from Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 7th ed., 2005)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The Cardiac Arrhythmia Suppression Trial (CAST) was a multicenter double-blind, placebo-controlled study designed to determine whether suppression of ventricular ectopic activity by means of antiarrhythmic drugs (encainide, flecainide or moricizine) after acute myocardial infarction would reduce the incidence of arrhythmic death." | 9.07 | Circadian pattern of arrhythmic death in patients receiving encainide, flecainide or moricizine in the Cardiac Arrhythmia Suppression Trial (CAST). ( Barker, AH; Brooks, MM; Capone, R; Echt, DS; Greene, HL; Liebson, PR; Mitchell, LB; Peters, RW, 1994) |
| "The effects of quinidine bisulfate (mean dose, 1483+/-240 mg) on the prevention of inducible and spontaneous ventricular fibrillation (VF) were prospectively evaluated in 25 patients (24 men, 1 woman; age, 19 to 80 years) with Brugada syndrome." | 8.82 | Efficacy of quinidine in high-risk patients with Brugada syndrome. ( Belhassen, B; Glick, A; Viskin, S, 2004) |
| "To assess the safety of long-term treatment with flecainide in patients with atrial fibrillation (AF), particularly with regard to sudden cardiac death (SCD) and proarrhythmic events." | 7.77 | The safety of flecainide treatment of atrial fibrillation: long-term incidence of sudden cardiac death and proarrhythmic events. ( Almroth, H; Andersson, T; Englund, A; Fengsrud, E; Friberg, L; Linde, P; Rosenqvist, M, 2011) |
| "The flecainide test is widely used in Brugada syndrome." | 7.72 | Flecainide test in Brugada syndrome: a reproducible but risky tool. ( Ceriotti, C; Galimberti, P; Gasparini, M; Mantica, M; Napolitano, C; Priori, SG; Simonini, S, 2003) |
| " We describe the case of a 62-year-old male with latent Brugada syndrome in whom the intravenous infusion of flecainide for paroxysmal atrial fibrillation caused ECG abnormalities similar to those of an acute septal myocardial infarction." | 7.72 | [Infusion of flecainide in a patient with atrial fibrillation and latent Brugada's syndrome has determined modifications of the electrocardiogram similar to those of a septal myocardial infarct]. ( Carotenuto, F; Cirillo, R; D'Errico, L; di Palma, F; Fontana, D; Granato, L; Pagano, V; Sestri, C; Vitiello, N, 2003) |
| "The Cardiac Arrhythmia Suppression Trial has shown that flecainide was associated with an increased incidence of sudden cardiac death in postinfarction patients." | 7.69 | Reentrant arrhythmias in the subacute infarction period. The proarrhythmic effect of flecainide acetate on functional reentrant circuits. ( Assadi, MA; Avitable, MJ; Caref, EB; el-Sherif, N; Isber, N; Ndrepepa, G; Patel, AI; Restivo, M; Yin, H, 1995) |
| "Six patients with short QT syndrome, five of whom had received an implantable cardioverter-defibrillator (ICD) and one child, were tested with different antiarrhythmic drugs, including flecainide, sotalol, ibutilide, and hydroquinidine, to determine whether they could prolong the QT interval into the normal range and thus prevent symptoms and arrhythmia recurrences." | 5.11 | Short QT syndrome: pharmacological treatment. ( Antzelevitch, C; Bianchi, F; Borggrefe, M; Brugada, R; Calò, L; Gaita, F; Giustetto, C; Haissaguerre, M; Schimpf, R; Wolpert, C, 2004) |
| "The Cardiac Arrhythmia Suppression Trial (CAST) was a multicenter double-blind, placebo-controlled study designed to determine whether suppression of ventricular ectopic activity by means of antiarrhythmic drugs (encainide, flecainide or moricizine) after acute myocardial infarction would reduce the incidence of arrhythmic death." | 5.07 | Circadian pattern of arrhythmic death in patients receiving encainide, flecainide or moricizine in the Cardiac Arrhythmia Suppression Trial (CAST). ( Barker, AH; Brooks, MM; Capone, R; Echt, DS; Greene, HL; Liebson, PR; Mitchell, LB; Peters, RW, 1994) |
| "The effects of quinidine bisulfate (mean dose, 1483+/-240 mg) on the prevention of inducible and spontaneous ventricular fibrillation (VF) were prospectively evaluated in 25 patients (24 men, 1 woman; age, 19 to 80 years) with Brugada syndrome." | 4.82 | Efficacy of quinidine in high-risk patients with Brugada syndrome. ( Belhassen, B; Glick, A; Viskin, S, 2004) |
| " A 59-year-old woman had a permanent pacemaker implanted after diagnosis of tachycardia-bradycardia syndrome, and her drug regimen of digoxin, verapamil, and warfarin was supplemented with flecainide to prevent paroxysmal atrial fibrillation." | 4.78 | Interference by antiarrhythmic agents with function of electrical cardiac devices. ( Bauman, JL; Ezri, M; Nazari, J; Tworek, DA, 1992) |
| " Her pregnancy was uncomplicated, and she was medically managed with metoprolol, flecainide, and verapamil." | 3.96 | Catecholaminergic polymorphic ventricular tachycardia in pregnancy: a case report. ( Contag, S; Schumer, A, 2020) |
| "To assess the safety of long-term treatment with flecainide in patients with atrial fibrillation (AF), particularly with regard to sudden cardiac death (SCD) and proarrhythmic events." | 3.77 | The safety of flecainide treatment of atrial fibrillation: long-term incidence of sudden cardiac death and proarrhythmic events. ( Almroth, H; Andersson, T; Englund, A; Fengsrud, E; Friberg, L; Linde, P; Rosenqvist, M, 2011) |
| "The flecainide test is widely used in Brugada syndrome." | 3.72 | Flecainide test in Brugada syndrome: a reproducible but risky tool. ( Ceriotti, C; Galimberti, P; Gasparini, M; Mantica, M; Napolitano, C; Priori, SG; Simonini, S, 2003) |
| " We describe the case of a 62-year-old male with latent Brugada syndrome in whom the intravenous infusion of flecainide for paroxysmal atrial fibrillation caused ECG abnormalities similar to those of an acute septal myocardial infarction." | 3.72 | [Infusion of flecainide in a patient with atrial fibrillation and latent Brugada's syndrome has determined modifications of the electrocardiogram similar to those of a septal myocardial infarct]. ( Carotenuto, F; Cirillo, R; D'Errico, L; di Palma, F; Fontana, D; Granato, L; Pagano, V; Sestri, C; Vitiello, N, 2003) |
| "These findings demonstrate that, in Brugada syndrome, spontaneous or ajmaline-induced changes in the surface ECG may be paralleled by significant variations in the right ventricular endocardial electrogram that may result in ICD malfunction." | 3.70 | Spatial and temporal heterogeneity of depolarization and repolarization may complicate implantable cardioverter defibrillator therapy in Brugada syndrome. ( Bella, PD; Carbucicchio, C; Schmidinger, H; Stix, G, 2000) |
| "The Cardiac Arrhythmia Suppression Trial has shown that flecainide was associated with an increased incidence of sudden cardiac death in postinfarction patients." | 3.69 | Reentrant arrhythmias in the subacute infarction period. The proarrhythmic effect of flecainide acetate on functional reentrant circuits. ( Assadi, MA; Avitable, MJ; Caref, EB; el-Sherif, N; Isber, N; Ndrepepa, G; Patel, AI; Restivo, M; Yin, H, 1995) |
| "Patients received oral flecainide or placebo twice daily, with the dosage guided by trough serum levels." | 2.84 | Efficacy of Flecainide in the Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia: A Randomized Clinical Trial. ( Batra, AS; Carboni, MP; Cerrone, M; Chen, H; Dzurik, MV; Ely, EW; Etheridge, SP; Fairbrother, DL; Fountain, D; Kannankeril, PJ; Kanter, RJ; Kaufman, ES; Kertesz, NJ; Knollmann, BC; Moore, JP; Priori, SG; Ro, PS; Roden, DM; Saarel, EV, 2017) |
| "Flecainide was reported to reduce exercise-induced ventricular arrhythmias (EIVA) in patients with ryanodine receptor-associated CPVT." | 2.78 | Flecainide therapy suppresses exercise-induced ventricular arrhythmias in patients with CASQ2-associated catecholaminergic polymorphic ventricular tachycardia. ( Blich, M; Boulos, M; Gepstein, L; Khoury, A; Lorber, A; Marai, I; Suleiman, M, 2013) |
| "Sudden cardiac death was observed in 16 patients, 8 patients in each group." | 2.72 | Determinants of sudden cardiac death in patients with persistent atrial fibrillation in the rate control versus electrical cardioversion (RACE) study. ( Crijns, HJ; Hagens, VE; Rienstra, M; Van Gelder, IC; Van Veldhuisen, DJ, 2006) |
| "The short QT syndrome is characterized by familial sudden death, short refractory periods, and inducible ventricular fibrillation." | 2.71 | Short QT Syndrome: a familial cause of sudden death. ( Bianchi, F; Borggrefe, M; Gaita, F; Giustetto, C; Grossi, S; Riccardi, R; Richiardi, E; Schimpf, R; Wolpert, C, 2003) |
| "Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited arrhythmogenic disease that can cause sudden cardiac death due to ventricular fibrillation (VF)." | 2.47 | Successful treatment of catecholaminergic polymorphic ventricular tachycardia with flecainide: a case report and review of the current literature. ( Bittner, A; Dechering, DG; Eckardt, L; Köbe, J; Kotthoff, S; Mönnig, G; Muszynski, A; Pott, C; Reinke, F; Schulze-Bahr, E; Wasmer, K; Zellerhoff, S, 2011) |
| "Current management of ventricular arrhythmias are considered in the light of these findings." | 2.38 | Treatment of ventricular arrhythmias after CAST. ( Tonkin, AM, 1992) |
| "Amiodarone was also more beneficial than individual antiarrhythmic therapy (mortality 10/100 patients, 10%)." | 2.38 | [What is the latest in anti-arrhythmia therapy?]. ( Gloor, HO, 1991) |
| "A novel familial arrhythmia syndrome, cardiac ryanodine receptor (RyR2) calcium release deficiency syndrome (CRDS), has recently been described." | 1.72 | Provocation Testing and Therapeutic Response in a Newly Described Channelopathy: RyR2 Calcium Release Deficiency Syndrome. ( Chen, SRW; Dreau, HMP; Ginks, MR; Guo, W; Li, Y; McGuire, K; Ormerod, JOM; Ormondroyd, E; Rajappan, K; Sarton, CNS; Taylor, J; Taylor, JC; Wang, R; Watkins, H; Wei, J, 2022) |
| "Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited disease characterized by polymorphic or bidirectional ventricular arrhythmias (VA) triggered by physical or emotional stress in young people with a structurally normal heart." | 1.48 | Flecainide Reduces Ventricular Arrhythmias in Patients With Genotype RyR2-positive Catecholaminergic Polymorphic Ventricular Tachycardia. ( Álvarez Acosta, L; Brugada Terradellas, J; Brugada Terradellas, R; Caballero Dorta, E; Campuzano Larrea, O; Groba Marco, MDV; Hernández Afonso, JS; Pérez, G; Wangüemert Pérez, F, 2018) |
| "Sudden cardiac death from ventricular arrhythmias is more common in adult patients with with heart failure compared with pediatric patients with heart failure." | 1.48 | Acute isoproterenol leads to age-dependent arrhythmogenesis in guinea pigs. ( Chau, S; Miyamoto, SD; Nau, S; Phillips, EK; Stauffer, BL; Sucharov, CC; Tompkins, C; Wilson, CE; Woulfe, KC; Zang, S, 2018) |
| "Flecainide testing was performed at each follow-up visits ≤6 months." | 1.42 | Brugada Syndrome Phenotype Elimination by Epicardial Substrate Ablation. ( Berruezo, A; Brugada, J; Ciconte, G; Giannelli, L; Manguso, F; Pappone, C; Santinelli, V; Vicedomini, G, 2015) |
| "Control animals developed premature ventricular complexes (PVCs) followed by ventricular tachycardia, which terminated in VF in 5 of the 8 dogs." | 1.39 | HBI-3000 prevents secondary sudden cardiac death. ( Lee, JY; Lucchesi, BR, 2013) |
| "Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an arrhythmogenic disease for which electrophysiological studies (EPS) have shown to be of limited value." | 1.37 | Postpacing abnormal repolarization in catecholaminergic polymorphic ventricular tachycardia associated with a mutation in the cardiac ryanodine receptor gene. ( Antzelevitch, C; Arad, M; Belhassen, B; Bhuiyan, ZA; El-Ani, D; Eldar, M; Fogelman, R; Glikson, M; Luria, D; Mannens, MM; Nof, E; Rosso, R; Viskin, S; Wilde, AA, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 10 (24.39) | 18.2507 |
| 2000's | 15 (36.59) | 29.6817 |
| 2010's | 13 (31.71) | 24.3611 |
| 2020's | 3 (7.32) | 2.80 |
| Authors | Studies |
|---|---|
| Ormerod, JOM | 1 |
| Ormondroyd, E | 1 |
| Li, Y | 1 |
| Taylor, J | 1 |
| Wei, J | 1 |
| Guo, W | 1 |
| Wang, R | 1 |
| Sarton, CNS | 1 |
| McGuire, K | 1 |
| Dreau, HMP | 1 |
| Taylor, JC | 1 |
| Ginks, MR | 1 |
| Rajappan, K | 1 |
| Chen, SRW | 1 |
| Watkins, H | 1 |
| Nozaki, Y | 1 |
| Kato, Y | 1 |
| Uike, K | 1 |
| Yamamura, K | 1 |
| Kikuchi, M | 1 |
| Yasuda, M | 1 |
| Ohno, S | 1 |
| Horie, M | 1 |
| Murayama, T | 1 |
| Kurebayashi, N | 1 |
| Horigome, H | 1 |
| Schumer, A | 1 |
| Contag, S | 1 |
| Kannankeril, PJ | 1 |
| Moore, JP | 1 |
| Cerrone, M | 1 |
| Priori, SG | 3 |
| Kertesz, NJ | 1 |
| Ro, PS | 1 |
| Batra, AS | 1 |
| Kaufman, ES | 1 |
| Fairbrother, DL | 1 |
| Saarel, EV | 1 |
| Etheridge, SP | 1 |
| Kanter, RJ | 1 |
| Carboni, MP | 1 |
| Dzurik, MV | 1 |
| Fountain, D | 1 |
| Chen, H | 1 |
| Ely, EW | 1 |
| Roden, DM | 1 |
| Knollmann, BC | 1 |
| Wangüemert Pérez, F | 1 |
| Hernández Afonso, JS | 1 |
| Groba Marco, MDV | 1 |
| Caballero Dorta, E | 1 |
| Álvarez Acosta, L | 1 |
| Campuzano Larrea, O | 1 |
| Pérez, G | 1 |
| Brugada Terradellas, J | 1 |
| Brugada Terradellas, R | 1 |
| Woulfe, KC | 1 |
| Wilson, CE | 1 |
| Nau, S | 1 |
| Chau, S | 1 |
| Phillips, EK | 1 |
| Zang, S | 1 |
| Tompkins, C | 1 |
| Sucharov, CC | 1 |
| Miyamoto, SD | 1 |
| Stauffer, BL | 1 |
| Lee, JY | 1 |
| Lucchesi, BR | 1 |
| Khoury, A | 1 |
| Marai, I | 1 |
| Suleiman, M | 1 |
| Blich, M | 1 |
| Lorber, A | 1 |
| Gepstein, L | 1 |
| Boulos, M | 1 |
| Gopinathannair, R | 1 |
| Maury, P | 1 |
| Audoubert, M | 1 |
| Cintas, P | 1 |
| Rollin, A | 1 |
| Duparc, A | 1 |
| Mondoly, P | 1 |
| Chiriac, AM | 1 |
| Acket, B | 1 |
| Zhao, X | 1 |
| Pasquié, JL | 1 |
| Cardin, C | 1 |
| Delay, M | 1 |
| Sadron, M | 1 |
| Carrié, D | 1 |
| Galinier, M | 1 |
| Davy, JM | 1 |
| Arne-Bès, MC | 1 |
| Raczka, F | 1 |
| Brugada, J | 2 |
| Pappone, C | 1 |
| Berruezo, A | 1 |
| Vicedomini, G | 1 |
| Manguso, F | 1 |
| Ciconte, G | 1 |
| Giannelli, L | 1 |
| Santinelli, V | 1 |
| Roston, TM | 1 |
| Cunningham, TC | 1 |
| Sanatani, S | 1 |
| Behr, ER | 1 |
| Camm, AJ | 1 |
| Lebreiro, A | 1 |
| Sousa, A | 1 |
| Silva, A | 1 |
| Campos, J | 1 |
| Maciel, MJ | 1 |
| Pott, C | 1 |
| Dechering, DG | 1 |
| Reinke, F | 1 |
| Muszynski, A | 1 |
| Zellerhoff, S | 1 |
| Bittner, A | 1 |
| Köbe, J | 1 |
| Wasmer, K | 1 |
| Schulze-Bahr, E | 1 |
| Mönnig, G | 1 |
| Kotthoff, S | 1 |
| Eckardt, L | 1 |
| Almroth, H | 1 |
| Andersson, T | 1 |
| Fengsrud, E | 1 |
| Friberg, L | 1 |
| Linde, P | 1 |
| Rosenqvist, M | 1 |
| Englund, A | 1 |
| Nof, E | 1 |
| Belhassen, B | 2 |
| Arad, M | 1 |
| Bhuiyan, ZA | 1 |
| Antzelevitch, C | 2 |
| Rosso, R | 1 |
| Fogelman, R | 1 |
| Luria, D | 1 |
| El-Ani, D | 1 |
| Mannens, MM | 1 |
| Viskin, S | 2 |
| Eldar, M | 1 |
| Wilde, AA | 1 |
| Glikson, M | 1 |
| Cabezón Ruiz, S | 1 |
| Errazquin Sáenz de Tejada, F | 1 |
| Pedrote Martínez, A | 1 |
| Morán Risco, JE | 1 |
| Marín Morgado, J | 1 |
| Fernández Pérez, JM | 1 |
| Gasparini, M | 1 |
| Mantica, M | 1 |
| Napolitano, C | 2 |
| Galimberti, P | 1 |
| Ceriotti, C | 1 |
| Simonini, S | 1 |
| Mok, NS | 1 |
| Chan, NY | 1 |
| Chahine, M | 1 |
| Baroudi, G | 1 |
| Vitiello, N | 1 |
| Cirillo, R | 1 |
| Fontana, D | 1 |
| Granato, L | 1 |
| Sestri, C | 1 |
| Pagano, V | 1 |
| D'Errico, L | 1 |
| Carotenuto, F | 1 |
| di Palma, F | 1 |
| Gaita, F | 2 |
| Giustetto, C | 2 |
| Bianchi, F | 2 |
| Wolpert, C | 2 |
| Schimpf, R | 2 |
| Riccardi, R | 1 |
| Grossi, S | 1 |
| Richiardi, E | 1 |
| Borggrefe, M | 2 |
| Haissaguerre, M | 1 |
| Calò, L | 1 |
| Brugada, R | 2 |
| Glick, A | 1 |
| Yokoi, H | 1 |
| Nishizaki, M | 1 |
| Fujii, H | 1 |
| Sakurada, H | 1 |
| Kimura, A | 1 |
| Hiraoka, M | 1 |
| Füessl, HS | 1 |
| Hagens, VE | 1 |
| Rienstra, M | 1 |
| Van Veldhuisen, DJ | 1 |
| Crijns, HJ | 1 |
| Van Gelder, IC | 1 |
| Kobza, R | 1 |
| Zuber, M | 1 |
| Erne, P | 1 |
| Junttila, MJ | 1 |
| Gonzalez, M | 1 |
| Lizotte, E | 1 |
| Benito, B | 1 |
| Vernooy, K | 1 |
| Sarkozy, A | 1 |
| Huikuri, HV | 1 |
| Brugada, P | 1 |
| Restivo, M | 1 |
| Yin, H | 1 |
| Caref, EB | 1 |
| Patel, AI | 1 |
| Ndrepepa, G | 1 |
| Avitable, MJ | 1 |
| Assadi, MA | 1 |
| Isber, N | 1 |
| el-Sherif, N | 1 |
| Peters, RW | 2 |
| Mitchell, LB | 1 |
| Brooks, MM | 1 |
| Echt, DS | 2 |
| Barker, AH | 1 |
| Capone, R | 1 |
| Liebson, PR | 1 |
| Greene, HL | 1 |
| Greenberg, HM | 1 |
| Dwyer, EM | 1 |
| Hochman, JS | 1 |
| Steinberg, JS | 1 |
| Kellen, JC | 1 |
| Ettinger, A | 1 |
| Todd, L | 1 |
| Brezsnyak, ML | 1 |
| Campion, J | 1 |
| McBride, R | 1 |
| Thomas, S | 1 |
| Corum, J | 1 |
| Schron, E | 1 |
| Swan, H | 1 |
| Piippo, K | 1 |
| Viitasalo, M | 1 |
| Heikkilä, P | 1 |
| Paavonen, T | 1 |
| Kainulainen, K | 1 |
| Kere, J | 1 |
| Keto, P | 1 |
| Kontula, K | 1 |
| Toivonen, L | 1 |
| Stix, G | 1 |
| Bella, PD | 1 |
| Carbucicchio, C | 1 |
| Schmidinger, H | 1 |
| Tonkin, AM | 1 |
| Gloor, HO | 1 |
| Somberg, J | 1 |
| Tworek, DA | 1 |
| Nazari, J | 1 |
| Ezri, M | 1 |
| Bauman, JL | 1 |
| Kerin, NZ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective Randomized Crossover Trial of Oral Flecainide for Catecholaminergic Polymorphic Ventricular Tachycardia[NCT01117454] | 14 participants (Actual) | Interventional | 2011-12-31 | Completed | |||
| Electrical Substrate Elimination in Brugada Syndrome. Results in 135 Consecutive Patients[NCT02641431] | 135 participants (Actual) | Interventional | 2015-11-16 | Completed | |||
| [NCT00000526] | Phase 3 | 0 participants | Interventional | 1986-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Hypothesis: the addition of oral flecainide to standard therapy will reduce ventricular ectopy and/or VT on treadmill exercise treadmill testing in patients with CPVT, compared to placebo plus standard therapy. (NCT01117454)
Timeframe: 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Flecainide | 2 |
| Placebo | 9 |
7 reviews available for flecainide and Death, Sudden, Cardiac
| Article | Year |
|---|---|
Advances in the diagnosis and treatment of catecholaminergic polymorphic ventricular tachycardia.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators, Implant | 2017 |
Successful treatment of catecholaminergic polymorphic ventricular tachycardia with flecainide: a case report and review of the current literature.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Calcium Channel Blockers; Child; Death, Sudden, | 2011 |
Efficacy of quinidine in high-risk patients with Brugada syndrome.
Topics: Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Cohort Studies; | 2004 |
Induced Brugada-type electrocardiogram, a sign for imminent malignant arrhythmias.
Topics: Adult; Age of Onset; Anesthetics; Antidepressive Agents, Tricyclic; Brugada Syndrome; Cocaine; Death | 2008 |
Treatment of ventricular arrhythmias after CAST.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Clinical Trials as Topic | 1992 |
[What is the latest in anti-arrhythmia therapy?].
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Clinical Tri | 1991 |
Interference by antiarrhythmic agents with function of electrical cardiac devices.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Death, Sudden, Cardiac; Digoxin; Drug Interactions; Ele | 1992 |
8 trials available for flecainide and Death, Sudden, Cardiac
| Article | Year |
|---|---|
Efficacy of Flecainide in the Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia: A Randomized Clinical Trial.
Topics: Adolescent; Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Cross-Over Studies; Death, Sudden, | 2017 |
Flecainide therapy suppresses exercise-induced ventricular arrhythmias in patients with CASQ2-associated catecholaminergic polymorphic ventricular tachycardia.
Topics: Adolescent; Anti-Arrhythmia Agents; Calsequestrin; Death, Sudden, Cardiac; DNA; Electrocardiography; | 2013 |
Short QT Syndrome: a familial cause of sudden death.
Topics: Adolescent; Adult; Aged; Arrhythmias, Cardiac; Atrial Fibrillation; Cardiac Complexes, Premature; Ch | 2003 |
Short QT syndrome: pharmacological treatment.
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Child; Death, Sudden, Cardiac | 2004 |
Determinants of sudden cardiac death in patients with persistent atrial fibrillation in the rate control versus electrical cardioversion (RACE) study.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2006 |
Circadian pattern of arrhythmic death in patients receiving encainide, flecainide or moricizine in the Cardiac Arrhythmia Suppression Trial (CAST).
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Aspirin; Circadian Rhythm; Death, Sudden, Cardia | 1994 |
Interaction of ischaemia and encainide/flecainide treatment: a proposed mechanism for the increased mortality in CAST I.
Topics: Angina Pectoris; Anti-Arrhythmia Agents; Databases, Factual; Death, Sudden, Cardiac; Drug Interactio | 1995 |
The Cardiac Arrhythmia Suppression Trial: Implications for nursing practice.
Topics: Aged; Anti-Arrhythmia Agents; Critical Care; Death, Sudden, Cardiac; Encainide; Female; Flecainide; | 1996 |
26 other studies available for flecainide and Death, Sudden, Cardiac
| Article | Year |
|---|---|
Provocation Testing and Therapeutic Response in a Newly Described Channelopathy: RyR2 Calcium Release Deficiency Syndrome.
Topics: Animals; Arrhythmias, Cardiac; Calcium; Channelopathies; Death, Sudden, Cardiac; Flecainide; Humans; | 2022 |
Co-Phenotype of Left Ventricular Non-Compaction Cardiomyopathy and Atypical Catecholaminergic Polymorphic Ventricular Tachycardia in Association With R169Q, a Ryanodine Receptor Type 2 Missense Mutation.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Calcium Signaling; Child; Child, Preschool; Dea | 2020 |
Catecholaminergic polymorphic ventricular tachycardia in pregnancy: a case report.
Topics: Death, Sudden, Cardiac; Female; Flecainide; Humans; Pregnancy; Ryanodine Receptor Calcium Release Ch | 2020 |
Flecainide Reduces Ventricular Arrhythmias in Patients With Genotype RyR2-positive Catecholaminergic Polymorphic Ventricular Tachycardia.
Topics: Adult; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; DNA Mutational Analysis; Electrocardiography; | 2018 |
Acute isoproterenol leads to age-dependent arrhythmogenesis in guinea pigs.
Topics: Action Potentials; Age Factors; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Death, Sudden | 2018 |
HBI-3000 prevents secondary sudden cardiac death.
Topics: Animals; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Disease Models, Animal; Dogs; Dose-Response | 2013 |
Flecainide in CASQ2-mediated catecholaminergic polymorphic ventricular tachycardia: the gift that keeps on giving.
Topics: Calsequestrin; Death, Sudden, Cardiac; Exercise Test; Female; Flecainide; Humans; Male; Tachycardia, | 2013 |
Prevalence of type 1 Brugada ECG pattern after administration of Class 1C drugs in patients with type 1 myotonic dystrophy: Myotonic dystrophy as a part of the Brugada syndrome.
Topics: Adult; Ajmaline; Brugada Syndrome; Death, Sudden, Cardiac; Defibrillators, Implantable; Electrocardi | 2014 |
Brugada Syndrome Phenotype Elimination by Epicardial Substrate Ablation.
Topics: Action Potentials; Adult; Anti-Arrhythmia Agents; Brugada Syndrome; Catheter Ablation; Death, Sudden | 2015 |
Letter by Behr and Camm regarding article, "Induced Brugada-type electrocardiogram, a sign for imminent malignant arrhythmias".
Topics: Adult; Age of Onset; Anesthetics; Antidepressive Agents, Tricyclic; Brugada Syndrome; Cocaine; Death | 2008 |
Atypical ST segment elevation and ventricular fibrillation without structural heart disease: a new electrocardiographic presentation of a channelopathy?
Topics: Anti-Arrhythmia Agents; Brugada Syndrome; Channelopathies; Death, Sudden, Cardiac; Defibrillators, I | 2010 |
The safety of flecainide treatment of atrial fibrillation: long-term incidence of sudden cardiac death and proarrhythmic events.
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Cardiovascular Agents; Coho | 2011 |
Postpacing abnormal repolarization in catecholaminergic polymorphic ventricular tachycardia associated with a mutation in the cardiac ryanodine receptor gene.
Topics: Adolescent; Adult; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Catheter Ablation; Child; Dea | 2011 |
[Normal conventional electrocardiogram with negative pharmacological stress test does not rule out Brugada syndrome].
Topics: Adult; Anti-Arrhythmia Agents; Bundle-Branch Block; Death, Sudden, Cardiac; Electrocardiography; Exe | 2003 |
Flecainide test in Brugada syndrome: a reproducible but risky tool.
Topics: Adolescent; Adult; Anti-Arrhythmia Agents; Bundle-Branch Block; Death, Sudden, Cardiac; Electrocardi | 2003 |
A newly characterized SCN5A mutation underlying Brugada syndrome unmasked by hyperthermia.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Bundle-Branch Block; Cholangitis; Death, Sudden, Cardi | 2003 |
[Infusion of flecainide in a patient with atrial fibrillation and latent Brugada's syndrome has determined modifications of the electrocardiogram similar to those of a septal myocardial infarct].
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Death, Sudden, Cardiac; Echocardiography; Electrocardio | 2003 |
[Can myocardial Na+ channel gene mutation be a prognostic factor for sudden death in asymptomatic Brugada syndrome?].
Topics: Death, Sudden, Cardiac; Electrocardiography; Flecainide; Humans; Male; Middle Aged; Mutation; NAV1.5 | 2004 |
Spontaneous T wave alternans in a patient with Brugada syndrome--responses to intravenous administration of class I antiarrhythmic drug, glucose tolerance test, and atrial pacing.
Topics: Adult; Anti-Arrhythmia Agents; Bundle-Branch Block; Cardiac Pacing, Artificial; Death, Sudden, Cardi | 2005 |
[Reason for worry: syncope in the morning].
Topics: Anti-Arrhythmia Agents; Circadian Rhythm; Death, Sudden, Cardiac; Diagnosis, Differential; Electroca | 2005 |
[What is your diagnosis? Brugada syndrome].
Topics: Adult; Anti-Arrhythmia Agents; Brugada Syndrome; Death, Sudden, Cardiac; Defibrillators, Implantable | 2006 |
Reentrant arrhythmias in the subacute infarction period. The proarrhythmic effect of flecainide acetate on functional reentrant circuits.
Topics: Animals; Arrhythmias, Cardiac; Cardiac Pacing, Artificial; Death, Sudden, Cardiac; Dogs; Electrocard | 1995 |
Arrhythmic disorder mapped to chromosome 1q42-q43 causes malignant polymorphic ventricular tachycardia in structurally normal hearts.
Topics: Adolescent; Adult; Anti-Arrhythmia Agents; Biopsy; Child; Chromosome Aberrations; Chromosome Disorde | 1999 |
Spatial and temporal heterogeneity of depolarization and repolarization may complicate implantable cardioverter defibrillator therapy in Brugada syndrome.
Topics: Adrenergic beta-Agonists; Adult; Ajmaline; Anti-Arrhythmia Agents; Bundle-Branch Block; Cardiac Paci | 2000 |
The spectrum of CAST I and II.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Death, Sudden, Cardiac; | 1991 |
Crime, misdemeanor, and arrhythmia decoding CAST.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Death, Sudden, Cardiac; Encainide; Flecainide; Heart V | 1991 |